The Combo-Drug Grift: Why Your DayQuil Is Mostly Placebo at a 6,000% Markup

The over-the-counter cold and flu market is built on selling combination products where most active ingredients do nothing. A $15 bottle of DayQuil, for instance, contains just one ingredient that works — a few cents’ worth of acetaminophen — bundled with dextromethorphan (which tests no better than placebo, and worse than honey) and oral phenylephrine (so ineffective the FDA proposed pulling it three years ago and still hasn’t). The markup on the one useful ingredient runs past 6,000%. Phenylephrine’s persistence is the clearest grift: after pseudoephedrine got locked behind the pharmacy counter due to its use in meth production, manufacturers swapped in a near-useless ingredient with a similar-sounding name and near-identical branding, and kept the profits flowing despite the FDA’s own data.

The article ties this to a four-decade breakdown in how the FDA evaluates efficacy. Once a weak drug is approved it is extraordinarily hard to remove, and approving under-tested drugs creates a perverse incentive — companies learn they can ship marginal products rather than solve hard problems. The libertarian counterargument, that patients should weigh the evidence themselves while the FDA only checks safety, ignores that consumers aren’t even reading labels or pricing alternatives, let alone parsing clinical trials.

The real danger is physical, not just financial. Because ineffective ingredients only sell when packaged with something that works, and because few cold remedies actually work, drugmakers load nearly every combo with acetaminophen. Patients grabbing multiple products then unknowingly stack identical ingredients. Acetaminophen overdoses drive over 50,000 ER visits and 500-plus deaths annually, roughly half of them unintentional — a direct consequence of a product category designed around placebos wrapped in one genuinely toxic-at-scale drug.